Concerns about the use of biosimilar granulocyte colony-stimulating factors for the mobilization of stem cells in normal donors: position of the World Marrow Donor Association.
about
Biosimilars in the management of neutropenia: focus on filgrastimClinical considerations for biosimilar antibodies.Ten years of biosimilars in Europe: development and evolution of the regulatory pathways.Granulocyte-colony stimulating factor for hematopoietic stem cell donation from healthy female donors during pregnancy and lactation: what do we know?Biosimilars 101: considerations for U.S. oncologists in clinical practiceStudy design: two long-term observational studies of the biosimilar filgrastim Nivestim™ (Hospira filgrastim) in the treatment and prevention of chemotherapy-induced neutropenia.Regulatory and clinical considerations for biosimilar oncology drugsProtecting the Health and Safety of Cell and Tissue DonorsBiosimilar granulocyte-colony-stimulating factor for healthy donor stem cell mobilization: need we be afraid?Safeguarding the long-term health of hematopoietic stem cell donors: a continuous and evolving process to maintain donor safety and trust.Long-term safety of granulocyte colony-stimulating factor in normal donors: is it all clear?Clinical experience with Zarzio® in Europe: what have we learned?Biosimilar G-CSF based mobilization of peripheral blood hematopoietic stem cells for autologous and allogeneic stem cell transplantationLong-active granulocyte colony-stimulating factor for peripheral blood hematopoietic progenitor cell mobilization.G-CSF: filgrastim, lenograstim and biosimilars.Related hematopoietic cell donor care: is there a role for unrelated donor registries?Biosimilar infliximab for inflammatory bowel disease: from concepts to clinical practice. Case study illustrated with CT-P13.Biosimilar G-CSF versus filgrastim and lenograstim in healthy unrelated volunteer hematopoietic stem cell donors.Evaluation of a biosimilar granulocyte colony-stimulating factor (filgrastim XM02) for peripheral blood stem cell mobilization and transplantation: a single center experience in Japan.Healthy donor hematopoietic stem cell mobilization with biosimilar granulocyte-colony-stimulating factor: safety, efficacy, and graft performance.Mobilization of autologous and allogeneic peripheral blood stem cells for transplantation in haematological malignancies using biosimilar G-CSF.Biosimilars of filgrastim in autologous stem cell transplant: reduction in granulocyte-colony stimulating factor costs, but similar effects on bone marrow recovery.We have a specific duty to maximise the safety of related donorsEthical issues and concerns about the use of biosimilar granulocyte colony-stimulating factors for the mobilisation of stem cells in normal donors.Use of a biosimilar granulocyte colony-stimulating factor for peripheral blood stem cell mobilization: an analysis of mobilization and engraftment.Biosimilar rhG-CSFs: how similar are they?Biosimilar granulocyte-colony-stimulating factor for mobilization of autologous peripheral blood stem cells in pediatric hematology-oncology patients.Short-term side effects and attitudes towards second donation: A comparison of related and unrelated haematopoietic stem cell donors.Epoetin Biosimilars in the Treatment of Chemotherapy-Induced Anemia: 10 Years' Experience Gained.Unrelated adult stem cell donor medical suitability: recommendations from the World Marrow Donor Association Clinical Working Group Committee.Comparison of biosimilar filgrastim with originator filgrastim for peripheral blood stem cell mobilization and engraftment in patients with multiple myeloma undergoing autologous stem cell transplantation.
P2860
Q26764906-93EF6F33-E976-472F-9B67-85BB8EFDCDF8Q30377239-235A3864-8E57-49EA-9F37-185BE6B67074Q33713947-AA760047-0996-4081-97BD-B5C7A8D7566EQ34320722-CC75B387-6152-490B-8A34-C2E54F867E09Q35000438-790C1BCE-156A-41D1-89F4-387EA8DE06DEQ35044368-0986043F-33E6-4666-9A7B-8DF4D21C37BCQ35505833-446FF66B-67EE-4C1D-B049-3E7482E3BC5DQ35551560-7675C1F6-7F31-4CC7-B54E-8399F164CCF0Q35835005-80A04E45-3165-40A2-A64F-5351F668338FQ36162892-0C2ADD69-839C-493E-825F-7DEF50FB54A5Q37996560-9006B016-B822-4D56-838D-E346FF34FC42Q38125609-34C33E77-074C-4448-A44A-075D213D4603Q38186025-34B46D51-CDAE-4D02-B76B-8A7CE2EE3A8DQ38193590-041F2112-9E5E-4E32-BDEF-434363EE3B1CQ38202661-457C9D62-F140-4CA8-8F3F-8F9B9FDB2D76Q38366630-0B6F0164-51C3-4516-A0A2-461CCDD907BAQ38591241-0982B5B0-FA7C-4A67-B054-C8BC9BA08D6BQ38628058-8BEE8570-8A6B-4401-BEE9-514B7A8A40BCQ38969947-75CAC8B4-860C-46D8-AC97-4E0D3F795E69Q39385304-02A0F021-5D3F-4372-9512-D889B9E57F99Q39504419-CBF3F22E-4166-48CD-B0F4-B7D4C968B43EQ42267665-166F58B5-5C88-4424-AB3F-EDBEC143699BQ42343632-B3F49BA4-9766-462D-8D6A-81CE76FE571EQ42343646-E0579326-349A-4C55-A750-81F0AF83F309Q43888363-88B1C679-FD2B-4008-A885-235C38CD4B69Q45788056-634617A7-BBE9-44CC-A671-21F08738E285Q46922809-E3157387-B65C-4436-99BA-07D6ED9AE0C6Q48192483-2CC1D7D3-B5A0-461C-BCBE-29F65A19F6E7Q50107702-7332579E-FD9F-478F-A163-2C97BDB9C0D3Q53091868-B4B18E5F-A282-42F2-A74D-CED1002BF6F5Q53426777-0E884852-F385-4FB9-95FD-A7D525BB8493
P2860
Concerns about the use of biosimilar granulocyte colony-stimulating factors for the mobilization of stem cells in normal donors: position of the World Marrow Donor Association.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
Concerns about the use of bios ...... orld Marrow Donor Association.
@en
Concerns about the use of bios ...... orld Marrow Donor Association.
@nl
type
label
Concerns about the use of bios ...... orld Marrow Donor Association.
@en
Concerns about the use of bios ...... orld Marrow Donor Association.
@nl
prefLabel
Concerns about the use of bios ...... orld Marrow Donor Association.
@en
Concerns about the use of bios ...... orld Marrow Donor Association.
@nl
P2093
P2860
P1433
P1476
Concerns about the use of bios ...... World Marrow Donor Association
@en
P2093
Bronwen E Shaw
Dennis L Confer
Derwood H Pamphilon
Michael A Pulsipher
P2860
P304
P356
10.3324/HAEMATOL.2011.045740
P577
2011-07-01T00:00:00Z